Analyst: Novo has cut to the bone now
With last week’s lowering of its long-term guidance, Novo Nordisk has cleared the air and paved the way for its new CEO, Lars Fruergaard Jørgensen, says Sydbank’s senior analyst Søren Løntoft Hansen.
BY LONNI LYNGE
The market did not exactly have lofty expectations for Novo Nordisk’s interim report for Q3 last week, but the fact that the insulin giant opted to cut its long-term earnings estimate in half nevertheless caught Søren Løntoft Hansen, senior analyst in Sydbank, off guard.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Another executive officer leaves Novo Nordisk
For abonnenter
Novo suffers regulatory setback in the US
For abonnenter
